The 2020 U.S. cancer screening deficit and the timing of adults' most recent screen: A population-based quasi-experiment

- Jason Semprini^{1,2} and Radhika Ranganthan³
- *For correspondence:

jason-semprini@uiowa.edu

- [†]The authors have no conflict of interests to disclose [‡]This work received no funding [§]Preliminary work for this study was presented at 10th Annual Symposium on Global Cancer Research (National Cancer Institute)
- **Present address:** § 145 N. Riverside Dr. N265, Iowa City, IA United States

- ⁶ University of Iowa, College of Public Health; ²University of Iowa, Department of Health
- Management Policy; ³University of South Carolina, School of Public Health
- **Abstract** In 2020, cancer screenings declined, then rebounded, resulting in a cancer screening deficit. The significance of this deficit, however, has yet to be quantified from a population health perspective. Our study addresses this evidence gap by examining how the pandemic changed the timing of American adults' most recent cancer screen. We obtained population-based, cancer screening data from the Behavioral Risk Factor Surveillance System. Mammograms, pap smears, and colonoscopies were each specified as a variable of mutually exclusive categories to indicate the timing since the most recent screening (never, 0-1 years, 1-2 years, 3+ years). Our quasi-experimental design restricts the sample to adults surveyed in January, February, or March. We then leverage a quirk in the BRFSS implementation and consider adults surveyed in the second year of each survey wave as the quasi-treatment cohort. Next, we constructed Linear and Logistic regression models which control for exogenous sociodemographic characteristics, state fixed effects, and temporal trends. Our results suggest that the deficit in 2020 was largely due to a one year delay among adults who receive annual screening, as the proportion of adults reporting a cancer screen in the past year declined by a nearly identical proportion of adults reporting their most recent cancer screen 1-2 years ago (3% to 4% points). However, the relative change was higher for mammograms and pap smears (17%) than colonoscopies (4%). We also found some evidence that the proportion of women reporting never having completed a mammogram declined in 2020, but the mechanisms for this finding should be further explored with the release of future data. Our estimates for the pandemic's effect on cancer screening rates are smaller than prior studies, but because we account for temporal trends we believe prior studies overestimated the effect of the pandemic and underestimated the overall downward 29

trend in cancer screenings across the country leading up to 2020.

2 Background

Despite the critical importance of early cancer detection, cancer screening rates in America are well below public policy targets, rife with racial and socioeconomic disparities, and despite considerable resources, stagnating (Suran 2022; Sabatino et al. 2022; Benavidez et al. 2021). Then came 2020, the first year of the COVID-19 Pandemic.

Even before the first wave of the COVID-19 Pandemic, predictions for cancer prevention and

control systems were dire. Given the elevated risk to cancer patients, either from adverse COVID19 outcomes or consequences of delayed cancer treatment, health systems needed to adapt to
ensure the safety of cancer patients during these initial months of the pandemic (Al-Quteimat and
Amer 2020; Anderson et al. 2020; Matos et al. 2021). These risk mitigation and continuity of care
policies may have prevented dramatic declines in the proportion of cancer patients receiving care
(Davidson et al. 2022; Semprini 2022). Unfortunately, cancer screening was less of a priority during
the early months of the public health emergency (DeJong, Katz, and Covinsky 2021).

Cancer screening could have been impacted by a number of federal, state, or local public health emergency policies, as well as by the changing priorities and capacities of health systems, and by individual social distancing behaviors (Cancino et al. 2020; Richards et al. 2020; DeJong, Katz, and Covinsky 2021). More recent research illuminated the role of financial stress and time costs as individual-level barriers to cancer screening, both of which may have compounded the strain on health systems attempting to resume cancer screening programs (Hanna et al. 2022; Peoples et al. 2022; Findling, Blendon, and Benson 2020).

There has been no shortage of evidence highlighting the stark decline in cancer screening services during the initial stages of the pandemic. Evidence from hospital records or insurance claims have suggested that, compared to pre-pandemic levels, mammograms, pap smears and colonoscopies declined 60% to 90% in March/April 2020 (Duszak et al. 2020; Bakouny et al. 2021; Staib, Catlett, and DaCosta Byfield 2021. However, subsequent research has found that in the later months of 2020, claims and records of cancer screenings returned to pre-pandemic levels (Chen et al. 2021); DeGroff et al. 2021; Labaki et al. 2021; McBain et al. 2021; Bello, Chang, and Massar-weh 2022; Drescher et al. 2022). Still, the pandemic created a major cancer screening deficit which may be difficult to address despite recent investment in "return to screening" initiatives (Chen et al. 2021; Hanna et al. 2022; Kelkar et al. 2022). Even as America returns to screening, some are being left behind (Mafi et al. 2022. In fact, among the adults reporting having delayed cancer screenings during the 2020 pandemic year only 25% have plans to return to screening (Suran 2022).

New Contributions

⁶⁵ Clearly, the COVID-19 pandemic created a cancer screening deficit in 2020. However, our understanding of this deficit is limited to hospital and claims based data, which is not necessarily a valid representation of the population's screening behavior. Moreover, the limited population-based patterns and rigorously assess the internal validity of our design.

research has attempted to quantify changing patterns in cancer screening by comparing rates in 2020 with 2019, or an average of prior years, essentially assuming that any change observed in 2020 was due to the pandemic (Fedewa et al. 2022; Dennis, Hsu, and Arrington 2021; Richardson 2022). This assumption, however, may not be valid as several factors could impact temporal screening patterns (Semprini 2022). Finally, few studies have attempted to infer the significance of this decline or deficit in cancer screenings in terms of how the time since the most recent cancer screen may have changed (Fedewa et al. 2022). This is critical for "return to screening" initiatives, as targeting or prioritizing health system capacity should consider the pandemic's effect on the timing of a cancer screen; not just for adults who delayed care for a year, but for adults who delayed for longer or even delayed initiating their first cancer screen.

Our study addresses these evidence gaps by designing a population-based quasi-experimental Event History Analysis, where we compare the year-by-year change in the timing of the most recent cancer screen among adults not exposed to the 2020 pandemic with the change in adults exposed to a full year of the pandemic. This approach allows us to control for temporal trends in screening

Results

Event-History Estimates (Linear Model)


In short, we find evidence that in 2020, exposure to the COVID-19 pandemic was associated with changing patterns of self-reported cancer screenings. Our estimates reveal that for the quasi-treatment cohort (late survey wave) in 2020, reports of a cancer screen in the past year declined as reports of a most recent cancer in the past 1-2 years increased. In 2020 for the quasi-treatment cohort, we also estimate a significant decline in self-reports of never having had a mammogram, which corresponds to a 33% relative decline from baseline rates of women reporting never having completed a mammogram. The absolute change for reporting a most recent mammogram in the past 1-2 years increased 4.2% points, which corresponds to a 17.5% increase from pre-pandemic rates of having reported a recent mammogram in 1-2 years. Similarly, the absolute change for reporting a most recent pap smear in the past 1-2 years increased 4.2% points, representing a 17.3% relative increase from pre-pandemic rates. Finally, reports of a colonoscopy in the past year were estimated to have declined by 3.5% points, a 4.3% relative change from baseline.

Table 1. Year-by-Year Differences in Screening Rates for Late Survey Cohort

		2010*Late		2012*Late		2014*Late		2016*Late		2020*Late		2020 Relative Change
	Never	-0.006	(0.018)	0.009	(0.016)	-0.013	(0.014)	-0.017	(0.012)	-0.029*	(0.013)	-33.0%
Mammogram	<1 Year	-0.011	(0.023)	-0.030	(0.024)	0.004	(0.023)	0.020	(0.021)	-0.021	(0.034)	-3.5%
	1-2 Years	-0.008	(0.020)	0.003	(0.018)	0.002	(0.020)	-0.000	(0.016)	0.031*	(0.015)	17.5%
	3+ Years	0.025	(0.021)	0.018	(0.018)	0.007	(0.012)	-0.002	(0.015)	0.020	(0.024)	11.5%
	Never	0.017	(0.010)	-0.011	(0.014)	-0.024*	(0.009)	-0.009	(0.010)	-0.011	(0.012)	-22.2%
D C	<1 Year	0.019	(0.023)	0.015	(0.025)	0.046*	(0.020)	-0.007	(0.015)	-0.043	(0.031)	-13.5%
Pap Smear	1-2 Years	-0.008	(0.015)	-0.014	(0.017)	0.003	(0.017)	0.024	(0.014)	0.042*	(0.019)	17.3%
	3+ Years	-0.028	(0.015)	0.010	(0.019)	-0.026	(0.017)	-0.008	(0.017)	0.012	(0.018)	10.2%
	Never	0.025	(0.017)	0.045*	(0.021)	0.042	(0.029)	-0.011	(0.022)	-0.010	(0.020)	-1.06
	<1 Year	-0.032	(0.022)	-0.012	(0.017)	-0.031	(0.030)	0.013	(0.018)	-0.035*	(0.016)	-4.3%
Colonoscopy	1-2 Years	0.016	(0.031)	-0.035	(0.020)	0.011	(0.025)	-0.009	(0.019)	0.030	(0.016)	3.8%
	3+ Years	-0.009	(0.020)	0.002	(0.012)	-0.023	(0.019)	0.008	(0.018)	0.015	(0.019)	2.1%

- Table 1 reports the year-by-year differences in cancer screening rates between the early and late survey cohorts. All analyses control for exogenous sociodemographic characteristics, state-level fixed effects, and temporal trends (year fixed effects). Robust standard errors were clustered at the state level and reported in parentheses. The relative change was estimated by computing the semi-elasticity
- (relative marginal effect) of belonging to the late survey cohort in 2020. *p < 0.05.
- Marginal Effect Estimates (Logistic Model)
- Figures 1-3 visually report the non-linear, average marginal effect estimates (derived from the results of the multinomial logistic model). Here, for each screening type and category, the average marginal effect of belonging to the quasi-treatment cohort for each year of the analysis. For our 2020 year of interest, we estimate average marginal effects significantly different than zero for mammograms in the past 1-2 years, pap smears in the past 1-2 years, and colonoscopies in the past year. However, we also see years when the average marginal effect of belonging to the quasi-treatment cohort was significantly different than zero in pre-pandemic years.

Figure 1: Marginal Effect of Late Survey Group on Rates of Most Recent Mammogram



- Figure 1 shows the marginal effect estimates for each category of the most recent self-reported mammograms for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.
- Figure 2: Marginal Effect of Late Survey Group on Rates of Most Recent Pap Smear




Figure 2 shows the marginal effect estimates for each category of the most recent self-reported pap smears for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.

Figure 3: Marginal Effect of Late Survey Group on Rates of Most Recent Colon/Sigmoidoscopy




Figure 3 shows the marginal effect estimates for each category of the most recent self-reported colonoscopies for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.

125 Sensitivity Checks

Our effect estimates and inference do not appear sensitive to linear or non-linear model specification. Supplemental table 2 shows the 2020*Late effect estimates for the linear probability model specification and the multinomial logistic model specification. For each type of screening and screening category, none of the estimates are significantly different from each other. Further, our inference (whether to reject the null hypothesis that screening rates were similar in 2020 for the late survey cohort) changed. The major takeaway from Table 2 in the supplemental file is that the effect estimates in the non-linear model were more precise (smaller standard errors) for significant estimates for mammograms and colonoscopies.

Now while the estimates do not change with regard to including state-fixed effects, clustering robust standard errors, and weighting our analyses, our inference would change depending on the preferred specification. In the supplemental file, table 3 shows the alternative designs (Alt 1 - no state fixed effects, Alt 2 - no state fixed effects, no clustering robust standard errors, Alt 3 - no state fixed effects, no clustering robust standard errors, and no probability sampling weights). For each of the three alternative specifications, the effect estimates for having never reported a mammogram in 2020 lose their significance. Moreover, for effect estimates of mammograms in the past year and past 1-2 years, inference appears to change across alternative specifications. Inference for the effect estimates on pap smears and colonoscopies also, slightly, varies across alternative specifications. However, more interest were the increased number of significant pre-trend test

statistics when excluding state fixed effects for both types of screenings. We suggest that this finding warrants inclusion the of the state-fixed effects to account for differential, time-invariant screening rates between quasi-treatment cohorts. Moreover, failing to account for clustering and weighting within each state may also add noise to our inference. Compared to our primary specification, our sensitivity analyses result in more differential pre-trend tests where we reject the null hypothesis (of no differential trends). Thus, we conclude that our primary specification is the most internally valid design.

151 Assessing internal validity

Comparability of quasi-treatment cohorts

Upon observing the unadjusted reports of a most recent cancer screen prior to 2020, we find little convincing evidence to believe that screening rates in the two groups differed before the first pandemic year. Supplemental Figures 2-4 visually depict the unadjusted cancer screening rates for our quasi-treatment (late survey wave) and quasi-control (early survey wave), for each year in our analyses. For each category of mammograms and pap smears, we see nearly identical trends and levels in the most recent screening from 2010-2018. For adults reporting never having completed a colonoscopy and adults reporting a colonscopy in the past year, we do see some possible non-common levels from 2010-14, but the trends and levels appear similar from 2016-2018.

The results of our two-sample proportion tests further validate our assumption, that these two quasi-treatment cohorts had simliar baseline screening rates. Note that Table 4 in the supplemental files does report a few screening outcomes with p-values under 0.05, but these test statistics are not significantly different than zero after accounting for multiple hypothesis testing (significance threshold p < 0.0125). Further, we fail to reject the null hypothesis that the sample composition of these two quasi-treatment groups are significantly different from each other (Table 5 in supplemental files).

Differential Trend Tests

We found evidence that screening rates in 2020 were significantly different between the two quasitreatment cohorts. To infer a causal effect, however, we rely on the assumption that, in the absence
of the pandemic, the change in screening rates would not have been observed for the late-survey
wave cohort. To test the validity of this assumption, we empirically tested for differential trends
prior to 2020. In the supplemental file, table 6 reports the year-by-year effect estimates (absolute
differences) between quasi-treatment cohorts after excluding year 2020 from the analysis. We
find no statistically significant differences in these effect estimates for mammograms. Moreover,
the joint test of significance for each mammogram category exceeds the threshold to reject the
null hypothesis that 2010, 2012, 2014, and 2016 coefficients equal zero (note, multiple hypothesis
testing threshold set at p < 0.0125).

We do however, detect the potential for differential trends in pap smears, specifically for adults reporting never having completed a pap smear and having completed a pap smear in the past year. The source of the potential pre-trend differences are observed in 2014. For both categories, we reject the null hypothesis that pap smear screening trends were similar prior to 2020 (p < 0.0125). Additionally, we detect the presence of differential trends for adults reporting their most recent colon/sigmoidoscopy three or more years prior. Again, the source of the differential pre-trend is observed in 2014. We reject the null hypothesis that, prior to 2020, reports of a colon/sigmoidoscopy three or more years ago were similar between the two quasi-treatment groups (p < 0.0125).

Discussion/Conclusion

183

185

186

The dire predictions and early evidence that cancer screening dramatically declined prompted investment and capacity for "return to screening" initiatives and patient prioritization policies (loung et al. 2022; Sprague et al. 2021). However, most early predictions focused on the initial decline. 190 as opposed to the subsequent rebound, and so did most of the early research. Even the research 191 which accounted for the rebound, failed to account for other, non-pandemic factors which could be 192 biasing the cancer screening deficit estimate. Our study does not claim that the pandemic had no 193 impact on cancer screening rates over the course of 2020. We found higher proportions of women completing their most recent mammogram and pap smear 1-2 years ago. We also found lower proportion of adults completing their colonoscopy in the past year. However, our point estimates are smaller than the most recent population-based research (Fedewa et al. 2022). We attribute this difference to the fact that our study includes adults exposed, not just to the entire pandemic year, but to the "rebound period". Additionally, our Event-History design attempts to control for 100 temporal changes which could be affecting cancer screening rates in ways unrelated to the pan-200 demic, which other studies may fail to identify with simple pre/post designs. The implications of 201 our findings suggest that "return to screening" initiatives and prioritization policies based on the 202 overestimated effects of the pandemic on screening, may fail to achieve greater screening adherence. This is especially true for adults who have been delaying recommended cancer screenings for three or more years, delays which started before the pandemic year. To advance cancer eguity, future research must continue monitoring the post-2020 cancer screening rebound to assess who is still delaying cancer screenings and how effective programs are mitigating these long-term delays. Finally, our results not only signal delayed cancer screening in 2020, but increased initia-208 tion. The proportion of women reporting to have never completed a mammogram declined for 209 our late cohort in 2020 (relative to the change in the early cohort). Did the "return to screening" 210 policies navigate new patients to their first mammogram? Or, was this decline merely a result of a 211 "lower population denominator" after a year of elevated excess mortality? Future data can help us understand the mechanisms influencing the post-COVID screening rebound, which will be critical for advancing efforts to improve early cancer detection in America well beyond this pandemic.

Methods and Materials

216 Data

We analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS), a cross-sectional random-digit-dialed, telephonic survey (both landline and cellphone) of nationally representative sample involving non-institutionalized civilian population, aged 18 years or older, who reside in the United States (CDC 2021). This population based self-reported, ongoing survey is conducted across all 50 states, DC and three US territories, which collects information on behavioral health risks, chronic conditions and the usage of preventive services covering more than 400,000 adult interviews each wave year.

24 Sample

Our study population included non-institutionalized adults 18 years or older, residing in the US (including DC), interviewed between January 1st to March 31st, for the even years (2010 – 2020). Based on BRFSS cancer module eligibility, we included adults who were asked whether or not they have received a mammogram, pap smear and/or sigmoidoscopy/colonoscopy screening services (CDC 2021). We then restricted our analysis to adults eligible for each respective cancer screen based on the United States Preventative Task Force: Mammograms (females age 40-74; Pap Smears (females age 25-64); and Colon/sigmoidoscopies (males and females age 45-79) (Moyer et al. 2012; Siu et al. 2016; Davidson et al. 2021). Participants from unknown US territories/jurisdictions, those who were interviewed between April 1st to December 31st for the years 2010 to 2020, those interviewed in the years which did not utilize cancer modules (odd years), were all excluded (Supplemental Figure 1).

Analytical Design

247

From the perspective of the analyst, the ideal experiment to evaluate how the COVID-19 pandemic impacted cancer screening would be to randomly assign adults into two groups: those exposed and those not exposed to the pandemic. After tracking individual screening behavior over time, any difference observed during the pandemic year (2020) would be attributed to the COVID-19 pandemic. This design is comically unrealistic. Unfortunately, quasi-experimental designs using "as-if" randomization into treatment and controls are also infeasible. Because the COVID-19 pandemic was a global event, everyone was exposed and everyone was impacted. Simple pre/post analyses have attempted to measure the change in cancer screening rates, but these approaches fail to account for other temporal factors which could be influencing screening rates in ways unrelated to the pandemic.

Rather than attempt to create different groups based on exposure to the pandemic during the pandemic year, we take a different approach by leveraging how BRFSS implements its cross-sectional survey over the course of 15 months. Selection into the BRFSS sample is random. When

25/

adults are surveyed, is also random. Therefore there is no reason to expect any observable differences in cancer screening behavior between adults queried early in a single year BRFSS survey wave and adults queried later in that same BRFSS survey wave; except however, during the COVID-19 pandemic year.

Our design begins by creating two distinct quasi-cohorts of adult BRFSS respondents. The first cohort only includes adults surveyed between January 1 and March 31 of the first year in each survey wave. We consider this "early" cohort the control group. Our second cohort only includes adults surveyed between January 1 and March 31 of the second year in each survey wave. We consider this "late" cohort the treatment group. Tables 2 (in the supplemental file) reports the cancer screening rates for both quasi-treatment and control cohorts for years 2010-2018. We test for significant differences in proportions between both groups and report the t-statistic and respective p-value to assess the comparability of these groups prior to 2020. We also conduct similar proportion tests for the sample composition of our control variables.

Prior to 2020, we hypothesize that screening behavior is not significantly different between our control and treatment groups. We also hypothesize that, prior to 2020, the trends in screening behavior do not differentially vary by group (see statistical analysis section below for details on these identification tests). Evidence that levels and trends did not vary between groups prior to 2020 supports our identification assumption: that any difference in screening rates observed in 2020 should be attributed to the COVID-19 pandemic.

Statistical Analysis For each of the three cancer screenings (mammograms, pap smears, and colonoscopies), we model the probability of self-reported cancer screening behavior as mutually exclusive categories related to the timing of the most recent screen. This approach not only allows us to model the change in probabilities over time, but also model how the distribution of cancer screening behavior changes between each timing category. Our initial specification models the probability of a recent cancer screen as a series of linear probability models.

1)
$$Y_{it}^{m} = P(Y^{m} = y | X_{i}, t = Y E A R, s = ST A T E)$$

Where Y_{its}^m is a binary variable indicating if the respondent reported a cancer screening in time interval m. X_i is a vector of control variables potentially impacting cancer screening rates, but exogenous to the COVID-19 pandemic. This set of exogenous dummy variables includes age (five-year age groups), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic other), education status (no highschool, high school degree only or GED, some college but no four-year degree, four-year college degree only or at least some graduate-level education and/or degree), whether the respondent is married, and whether the respondent is male. To account for secular trends in cancer screening, each model includes YEAR, a vector of binary fixed-effects variables indicating the survey wave year. These survey wave fixed effects account for temporal trends

in cancer screening. Finally, to account for time-invariant, regional behaviors, policies, and health systems impacting cancer screening, each model includes s, a vector of binary fixed-effects variables indicating the state of residence for each respondent.

We then estimate the incremental effect of the COVID-19 pandemic on screening behavior Y_{its}^m

290 2)
$$\Delta SCREENING^m = \frac{\Delta Y_{lis}^m}{\Delta PANDEMIC} = \frac{\Delta Y_{lis}^m}{\Delta (2020) (reatment)}$$

Where the estimated effect equals a change in Y_{its}^m given an incremental change in pandemic status (modeled as the incremental change of a dummy variable indicating if the year is 2020, for adults in the treatment group). Rather than implement a simple pre/post design, we explicitly allow the screening behavior in the treatment group to vary from the screening behavior in the control group for each year of the analysis (Clarke and Tapia-Schythe 2021). The event history study model is defined as:

B identifies the average association between cancer screening behavior Y^m for adults surveyed

3)
$$Y_{its}^m = \beta * YEAR_t' * TREATED_i + YEAR_t' + X_I' + STATE_S' + e_{its}$$

in the later part of each BRFSS survey wave. Using 2019 as the arbitrary baseline category, our event history analysis yields five B parameters (2010*Late, 2012*Late, 2014*Late, 2016*Late, and 2020*Late) This approach also allows us to test if $\Delta Y_{in}^m = \Delta PANDEMIC = (2020|control) = 0$ 301 (Borusvak, Jaravel, and Spiess 2022). More importantly, we can now visually assess and empiri-302 cally test our identification assumptions (Marcus and SantAnna 2021). Following best practice, we 303 formally conduct pre-treatment differential trend tests by excluding responses in the 2020 survey wave and then recompute equation 3 (Freyaldenhoven, Hansen, and Shapiro 2019). In addition to reporting for each YEAR*TREATED coefficient, we calculate robust Wald statistics (with Bonferonni correction) to test if the trends in cancer screening rates between quasi-treatment and control cohorts jointly equalled zero (Armstrong 2014). Any significant results from these pre-treatment tests would suggest that cancer screening behaviors were differentially changing for treatment. compared to control cohorts, in ways unrelated to the COVID-19 pandemic. Conversely, null re-310 sults provide confidence in the strength of our identifying assumption and supports the validity of 311 our study design. 312 All analyses incorporate BRFSS supplied sampling weights, estimate standard errors robust to 313

heteroskedasticity, and cluster the robust standard errors at the state level (Abadie et al. 2017; Cameron and Miller 2015). The Bonferonni correction method was used to adjust for multiple

hypothesis testing for group differences and pre-treatment joint Wald tests (Armstrong 2014.

Alternative Specifications

Because of its ability to consistently model time-trends and group (i.e., state) fixed effects, the linear probability model is typically the preferred specification in the quasi-experimental literature. However, analytical issues may arise if the linear predictions are estimating potential outcomes 320 outside the bounds of zero and one. In the presence of these nonsensical predictions, the lin-321 ear probability model may be yielding biased estimates. To confront this threat, we construct an 322 alternative set of specifications and model the probability of a recent cancer diagnosis with a multi-323 nomial logistic regression model. After comparing the predicted probabilities of these nonlinear 324 models with the predictions of our linear model, we use the coefficients in the nonlinear models to estimate the average incremental effect of the treatment group (compared to the control group) in 326 each year on the probability of each cancer outcome (Williams 2012). We also extend this marginal analysis to estimate the semi-elasticity, or relative change from baseline screening rates, for the treatment group in 2020 (Williams 2012). To support our inference, we test if the point estimates 320 and standard errors in our linear models are significantly different from the estimates in the non-330 linear specifications. A final set of sensitivity analyses relax the model assumptions by 1) removing 331 the state-specific fixed effects. 2) remove state-specific fixed effects and estimate (unclustered) ro-332 bust standard errors, 3) remove state-fixed effects, estimate (unclustered) robust standard errors, 333 and ignore probability sampling weights.

```
References
335
     Abadie, Alberto, Susan Athey, Guido W. Imbens, and Jeffrey Wooldridge. When Should You Adjust Standard Errors
          for Clustering? Working Paper 24003. Series: Working Paper Series. National Bureau of Economic Research,
          November 2017. Accessed June 2, 2022. https://doi.org/10.3386/w24003. https://www.nber.org/papers/w24003.
338
     Anderson, Roy M., Hans Heesterbeek, Don Klinkenberg, and T. Déirdre Hollingsworth. "How will country-based
339
          mitigation measures influence the course of the COVID-19 epidemic?" Publisher: Elsevier, The Lancet 395,
340
          no. 10228 (March 21, 2020): 931–934. ISSN: 0140-6736, 1474-547X, accessed April 3, 2020. https://doi.org/10.
341
          1016/S0140-6736(20)30567-5. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30567-5/abstract.
342
     Armstrong, RA. "When to use the Bonferroni correction." Ophthalmic Physiol Opt, April 2014. Accessed June 2,
          2022. https://doi.org/10.1111/opo.12131. https://pubmed.ncbi.nlm.nih.gov/24697967/.
344
     Bakouny, Ziad, Marco Paciotti, Andrew L. Schmidt, Stuart R. Lipsitz, Toni K. Choueiri, and Ouoc-Dien Trinh.
345
          "Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic." IAMA Oncology 7. no. 3
          (March 1, 2021): 458-460. ISSN: 2374-2437, accessed November 18, 2021. https://doi.org/10.1001/jamaoncol.
347
          2020.7600. https://doi.org/10.1001/jamaoncol.2020.7600.
348
     Bello, Ricardo J., George J. Chang, and Nader N. Massarweh. "Colorectal Cancer Screening in the USStill Putting
          the Cart Before the Horse?" JAMA Oncology, May 5, 2022. ISSN: 2374-2437, accessed June 2, 2022. https:
350
          //doi.org/10.1001/jamaoncol.2022.0500. https://doi.org/10.1001/jamaoncol.2022.0500.
351
     Benavidez, Gabriel A., Ania Zgodic, Whitney E. Zahnd, and Ian M. Eberth, "Disparities in Meeting USPSTF Breast,
          Cervical, and Colorectal Cancer Screening Guidelines Among Women in the United States." Preventing
353
          Chronic Disease 18 (April 15, 2021): E37. ISSN: 1545-1151, accessed March 2, 2022. https://doi.org/10.5888/
354
          pcd18.200315. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051853/.
355
     Bitler, Marianne P., Christopher S, Carpenter, and Danea Horn, "Effects of the Colorectal Cancer Control Pro-
356
          gram." Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/hec.4397, Health Economics 30, no. 11 (2021):
357
          2667-2685. ISSN: 1099-1050, accessed June 2, 2022. https://doi.org/10.1002/hec.4397. https://onlinelibrary.wiley.
358
          com/doi/abs/10.1002/hec.4397.
359
     Borusyak, Kirill, Xavier Jaravel, and Jann Spiess, Revisiting Event Study Designs; Robust and Efficient Estimation,
360
          SSRN Scholarly Paper 2826228. Rochester, NY: Social Science Research Network, April 19, 2022. Accessed
361
          June 2, 2022. https://doi.org/10.2139/ssrn.2826228. https://papers.ssrn.com/abstract=2826228.
362
     Cameron, A. Colin, and Douglas L. Miller, "A Practitioners Guide to Cluster-Robust Inference," Publisher: Univer-
363
          sity of Wisconsin Press, Journal of Human Resources 50, no. 2 (March 31, 2015): 317-372. ISSN: 0022-166X,
364
          1548-8004, accessed June 2, 2022, https://doi.org/10.3368/jhr.50.2.317, http://jhr.uwpress.org/content/50/2/317,
     Cancino, Ramon S., Zhaohui Su, Ruben Mesa, Gail E, Tomlinson, and ling Wang, "The Impact of COVID-19 on
366
          Cancer Screening: Challenges and Opportunities," Company: IMIR Cancer Distributor: IMIR Cancer Institu-
367
          tion: IMIR Cancer Label: IMIR Cancer Publisher: JMIR Publications Inc., Toronto, Canada, JMIR Cancer 6, no.
          2 (October 29, 2020); e21697. Accessed June 2, 2022. https://doi.org/10.2196/21697. https://cancer.imir.org/2020/
360
          2/e21697.
370
     CDC. "Behavioral Risk Factor Surveillance System [2010-2020]," 2021. Accessed January 2, 2022. https://www.cdc.
```

gov/brfss/annual data/annual 2020.html.

372

```
Chen, Ronald C., Kevin Haynes, Simo Du, John Barron, and Aaron J. Katz. "Association of Cancer Screening Deficit
          in the United States With the COVID-19 Pandemic." JAMA Oncology 7, no. 6 (June 1, 2021): 878-884. ISSN:
374
          2374-2437, accessed March 11, 2022, https://doi.org/10.1001/jamaoncol.2021.0884, https://doi.org/10.1001/
375
          jamaoncol.2021.0884.
376
     Clarke, Damian, and Kathya Tapia-Schythe. "Implementing the panel event study." Publisher: SAGE Publications,
377
          The Stata Journal 21, no. 4 (December 1, 2021): 853-884. ISSN: 1536-867X, accessed June 2, 2022. https:
378
          //doi.org/10.1177/1536867X211063144. https://doi.org/10.1177/1536867X211063144.
379
     Davidson, Karina W., Michael J. Barry, Carol M. Mangione, Michael Cabana, Aaron B. Caughey, Esa M. Davis,
          Katrina E. Donahue, et al. "Screening for Colorectal Cancer: US Preventive Services Task Force Recommen-
381
          dation Statement." IAMA 325, no. 19 (May 18, 2021); 1965–1977. ISSN: 1538-3598. https://doi.org/10.1001/
382
          jama.2021.6238.
     Davidson, Nancy E., Karen E. Knudsen, Shelley Fuld Nasso, Randall Oyer, Steve Pergam, Lara Strawbridge, and
384
          Lawrence Shulman. "Cancer Care at the Beginning of the COVID-19 Pandemic: Effects on Patients and
385
          Early Interventions to Mitigate Stresses on Care." The Cancer Journal 28, no. 2 (April 2022): 107–110. ISSN:
          1528-9117, accessed June 2, 2022, https://doi.org/10.1097/PPO.00000000000586, https://journals.lww.com/
387
          journalppo/Fulltext/2022/03000/Cancer_Care_at_the_Beginning_of_the_COVID_19.5.aspx.
388
     DeGroff, A., J. Miller, K. Sharma, J. Sun, W. Helsel, W. Kammerer, T. Rockwell, et al. "COVID-19 impact on screening
          test volume through the National Breast and Cervical Cancer early detection program, January June 2020, in
390
          the United States." Preventive Medicine, From disruption to recovery: The Impact of the COVID-19 Pandemic
391
          on Cancer Screening, 151 (October 1, 2021): 106559. ISSN: 0091-7435, accessed June 2, 2022. https://doi.
392
          org/10.1016/j.ypmed.2021.106559. https://www.sciencedirect.com/science/article/pii/S0091743521001432.
303
     Delong, Colette, Mitchell H. Katz, and Kenneth Covinsky. "Deferral of Care for Serious NonCOVID-19 Conditions:
394
          A Hidden Harm of COVID-19." JAMA Internal Medicine 181, no. 2 (February 1, 2021): 274. ISSN: 2168-6106,
395
          accessed April 5, 2022. https://doi.org/10.1001/jamainternmed.2020.4016. https://doi.org/10.1001/jamainternmed.2020.
          4016.
397
     Dennis, Leslie K., Chiu-Hsieh Hsu, and Amanda K. Arrington. "Reduction in Standard Cancer Screening in 2020
398
          throughout the U.S." Number: 23 Publisher: Multidisciplinary Digital Publishing Institute, Cancers 13, no.
          23 (January 2021): 5918. ISSN: 2072-6694, accessed June 2, 2022. https://doi.org/10.3390/cancers13235918.
400
          https://www.mdpi.com/2072-6694/13/23/5918.
401
     Drescher, Charles W., Adam J. Bograd, Shu-Ching Chang, Roshanthi K. Weerasinghe, Ann Vita, and R. Bryan Bell.
402
          "Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational
403
          study with extended follow-up." Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34067, Can-
404
          cer 128, no. 7 (2022): 1475-1482. ISSN: 1097-0142, accessed June 2, 2022. https://doi.org/10.1002/cncr.34067.
405
          https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34067.
406
     Duszak, Richard, Jeff Maze, Candice Sessa, Howard B. Fleishon, Lauren P. Golding, Gregory N. Nicola, and Danny
407
          R. Hughes. "Characteristics of COVID-19 Community Practice Declines in Noninvasive Diagnostic Imaging
408
          Professional Work." Publisher: Elsevier, Journal of the American College of Radiology 17, no. 11 (November 1,
409
          2020): 1453-1459. ISSN: 1546-1440, 1558-349X, accessed June 2, 2022. https://doi.org/10.1016/j.jacr.2020.06
410
          031. https://www.jacr.org/article/S1546-1440(20)30742-0/fulltext.
411
```


```
Fedewa, Stacey A., Jessica Star, Priti Bandi, Adair Minihan, Xuesong Han, K. Robin Yabroff, and Ahmedin Jemal.
412
               "Changes in Cancer Screening in the US During the COVID-19 Pandemic." JAMA Network Open 5, no. 6 (June
413
               2022); e2215490-e2215490, ISSN: 2574-3805, https://doi.org/10.1001/jamanetworkopen.2022.15490, eprint; https://doi.org/10.1001
414
               //jamanetwork.com/journals/jamanetworkopen/articlepdf/2792956/fedewa\ 2022\ oi\ 220453\ 1653581780.1564.pdf.
415
               https://doi.org/10.1001/jamanetworkopen.2022.15490.
416
       Fedewa, Stacey A., K. Robin Yabroff, Priti Bandi, Robert A. Smith, Nigar Nargis, Zhiyuan Zheng, Jeffrey Drope, and
417
               Ahmedin Jemal. "Unemployment and cancer screening: Baseline estimates to inform health care delivery
418
               in the context of COVID-19 economic distress." Cancer 128, no. 4 (February 15, 2022): 737-745. ISSN: 1097-
419
               0142. https://doi.org/10.1002/cncr.33966.
420
       Findling, Mary G., Robert I. Blendon, and John M. Benson. "Delayed Care with Harmful Health Consequences-
421
               Reported Experiences from National Surveys During Coronavirus Disease 2019." JAMA Health Forum 1, no.
               12 (December 14, 2020): e201463. ISSN: 2689-0186, accessed March 11, 2022. https://doi.org/10.1001/
423
               jamahealthforum.2020.1463. https://doi.org/10.1001/jamahealthforum.2020.1463.
424
       Freyaldenhoven, Simon, Christian Hansen, and Jesse M. Shapiro. "Pre-event Trends in the Panel Event-Study
425
               Design." American Economic Review 109, no. 9 (September 2019): 3307-3338, ISSN: 0002-8282, accessed
426
               June 2, 2022. https://doi.org/10.1257/aer.20180609. https://www.aeaweb.org/articles?id=10.1257/aer.20180609.
427
       Hanna, Karim, Brandy L. Arredondo, Melody N. Chavez, Carley Geiss, Emma Hume, Laura Szalacha, Shannon M.
428
               Christy, et al. "Cancer Screening Among Rural and Urban Clinics During COVID-19: A Multistate Qualitative
429
               Study." Publisher: Wolters Kluwer, ICO Oncology Practice, March 7, 2022, OP.21.00658. ISSN: 2688-1527,
430
               accessed March 29, 2022. https://doi.org/10.1200/OP.21.00658. https://ascopubs.org/doi/full/10.1200/OP.21.00658.
431
       Joung, Rachel H., Heidi Nelson, Timothy W. Mullett, Scott H. Kurtzman, Sarah Shafir, James B. Harris, Katharine A.
432
               Yao, Brian C. Brajcich, Karl Y. Bilimoria, and William G. Cance. "A national quality improvement study identi-
433
               fying and addressing cancer screening deficits due to the COVID-19 pandemic." _Eprint: https://onlinelibrary.wiley.coi
434
               Cancer 128, no. 11 (2022); 2119–2125. ISSN: 1097-0142, accessed June 2, 2022. https://doi.org/10.1002/cncr.
435
               34157. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34157.
436
       Kelkar, Amar H., Jing Zhao, Shu Wang, and Christopher R. Cogle. "Impact of the COVID-19 Pandemic on Colorec-
437
               tal and Prostate Cancer Screening in a Large U.S. Health System." Number: 2 Publisher: Multidisciplinary
438
               Digital Publishing Institute, Healthcare 10, no. 2 (February 2022): 264. ISSN: 2227-9032, accessed June 2,
439
               2022. https://doi.org/10.3390/healthcare10020264. https://www.mdpi.com/2227-9032/10/2/264.
440
       Labaki, Chris, Ziad Bakouny, Andrew Schmidt, Stuart R. Lipsitz, Timothy R. Rebbeck, Quoc-Dien Trinh, and Toni K.
441
               Choueiri. "Recovery of cancer screening tests and possible associated disparities after the first peak of the
442
               COVID-19 pandemic." Cancer Cell 39, no. 8 (August 9, 2021): 1042-1044. ISSN: 1535-6108, accessed June 2,
443
               2022. https://doi.org/10.1016/j.ccell.2021.06.019. https://www.sciencedirect.com/science/article/pii/S153561082100341X.
444
       Mafi, John N., Melody Craff, Sitaram Vangala, Thomas Pu, Dale Skinner, Cyrus Tabatabai-Yazdi, Anikia Nelson,
445
               et al. "Trends in US Ambulatory Care Patterns During the COVID-19 Pandemic, 2019-2021." JAMA 327, no. 3
446
               (January 18, 2022): 237-247. ISSN: 0098-7484, accessed June 2, 2022. https://doi.org/10.1001/jama.2021.24294.
447
               https://doi.org/10.1001/jama.2021.24294.
448
       Marcus, Michelle, and Pedro H. C. SantAnna. "The Role of Parallel Trends in Event Study Settings: An Applica-
449
               tion to Environmental Economics." Publisher: The University of Chicago Press, Journal of the Association of
450
               Environmental and Resource Economists 8, no. 2 (March 2021): 235-275. ISSN: 2333-5955, accessed June 2,
451
               2022. https://doi.org/10.1086/711509. https://www.journals.uchicago.edu/doi/full/10.1086/711509.
452
```

```
Matos, Leandro L., Carlos Henrique Q. Forster, Gustavo N. Marta, Gilberto Castro Junior, John A. Ridge, Daisy
453
               Hirata, Adalberto Miranda-Filho, et al. "The hidden curve behind COVID-19 outbreak; the impact of delay
               in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and
455
               neck cancer model." Cancer causes & control: CCC 32, no. 5 (May 2021): 459-471. ISSN: 1573-7225. https://
456
               //doi.org/10.1007/s10552-021-01411-7.
457
        McBain, Ryan K., Jonathan H. Cantor, Anupam B. Jena, Megan F. Pera, Dena M. Bravata, and Christopher M.
458
               Whaley, "Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic." Journal
459
               of General Internal Medicine 36, no. 6 (June 1, 2021): 1829–1831. ISSN: 1525-1497, accessed June 2, 2022.
460
               https://doi.org/10.1007/s11606-021-06660-5. https://doi.org/10.1007/s11606-021-06660-5.
461
        Moyer, Virginia A., and U.S. Preventive Services Task Force. "Screening for cervical cancer: U.S. Preventive Ser-
462
               vices Task Force recommendation statement." Annals of Internal Medicine 156, no. 12 (June 19, 2012): 880-
               891, W312. ISSN: 1539-3704. https://doi.org/10.7326/0003-4819-156-12-201206190-00424.
464
        Peoples, Anita R., Laura B. Oswald, Jennifer Ose, Bailee Daniels, Caroline Himbert, Cassandra A. Hathaway, Bil-
465
               jana Gigic, et al. "Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health
               behaviors, and perceptions." Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/jrh.12648, The Jour-
467
               nal of Rural Health n/a (n/a 2022). ISSN: 1748-0361, accessed March 29, 2022. https://doi.org/10.1111/jrh.12648.
468
               https://onlinelibrary.wiley.com/doi/abs/10.1111/jrh.12648.
        Al-Quteimat, Osama M., and Amer Mustafa Amer. "The Impact of the COVID-19 Pandemic on Cancer Patients."
470
               American Journal of Clinical Oncology 43, no. 6 (June 2020): 452-455. ISSN: 0277-3732, accessed Novem-
471
               ber 18, 2021. https://doi.org/10.1097/COC.0000000000000712. https://journals.lww.com/amjclinicaloncology/fulltext/
472
               2020/06000/the_impact_of_the_covid_19_pandemic_on_cancer.12.aspx.
473
        Richards, Mike, Michael Anderson, Paul Carter, Benjamin L. Ebert, and Elias Mossialos. "The impact of the COVID-
474
               19 pandemic on cancer care." Number: 6 Publisher: Nature Publishing Group, Nature Cancer 1, no. 6 (June
475
               2020): 565-567. ISSN: 2662-1347, accessed April 6, 2022. https://doi.org/10.1038/s43018-020-0074-y. https://doi.org/10.1038/s43018-020-0074-y.
476
               //www.nature.com/articles/s43018-020-0074-y.
477
        Richardson, Lisa C. "Adults Who Have Never Been Screened for Colorectal Cancer, Behavioral Risk Factor Surveil-
478
               lance System, 2012 and 2020." Preventing Chronic Disease 19 (2022). ISSN: 1545-1151, accessed June 2, 2022.
479
               https://doi.org/10.5888/pcd19.220001. https://www.cdc.gov/pcd/issues/2022/22 0001.htm.
480
        Sabatino, Susan A., Trevor D. Thompson, Mary C. White, Jean A. Shapiro, Tainya C. Clarke, Jennifer M. Croswell,
481
               and Lisa C. Richardson. "Cancer Screening Test Use8213; U.S., 2019." American Journal of Preventive Medicine,
482
               April 22, 2022. ISSN: 0749-3797, accessed June 2, 2022. https://doi.org/10.1016/j.amepre.2022.02.018. https://doi.org/10.1016/j.amepre.2022.018. https://doi.org/1
483
               //www.sciencedirect.com/science/article/pii/S0749379722001520.
484
        Schoenborn, Nancy L., Cynthia M. Boyd, and Craig E. Pollack, "Impact of the COVID-19 pandemic on cancer
               screening attitudes, intentions, and behaviors in older adults." Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.11
486
               Journal of the American Geriatrics Society 70, no. 1 (2022): 67-69. ISSN: 1532-5415, accessed June 2, 2022.
487
               https://doi.org/10.1111/jgs.17449. https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.17449.
488
        Semprini, Jason. "How Did the Covid-19 Pandemic Impact Cancer Prevention and Treatment? Examining Nation-
489
               ally Representative Survey Data." Publisher: Wolters Kluwer, JCO Global Oncology 8 (Supplement_1 2022):
490
               18-18. Accessed June 2, 2022. https://doi.org/10.1200/GO.22.24000. https://ascopubs.org/doi/abs/10.1200/GO.22.
491
               24000.
492
```


```
Semprini, Jason. How did the COVID-19 Pandemic impact self-reported cancer screening rates in 12 Midwestern
493
          states? Type: article. medRxiv, April 18, 2022. Accessed June 2, 2022. https://doi.org/10.1101/2022.04.13.
          22273837. https://www.medrxiv.org/content/10.1101/2022.04.13.22273837v1.
495
     Siu, Albert L., and U.S. Preventive Services Task Force. "Screening for Breast Cancer: U.S. Preventive Services
496
          Task Force Recommendation Statement." Annals of Internal Medicine 164, no. 4 (February 16, 2016): 279-
          296. ISSN: 1539-3704. https://doi.org/10.7326/M15-2886.
498
     Sprague, Brian L., Ellen S. O'Meara, Christoph I. Lee, Janie M. Lee, Louise M. Henderson, Diana S. M. Buist,
499
          Nila Alsheik, et al. "Prioritizing breast imaging services during the COVID pandemic: A survey of breast
          imaging facilities within the Breast Cancer Surveillance Consortium." Preventive Medicine, From disruption
501
          to recovery: The Impact of the COVID-19 Pandemic on Cancer Screening, 151 (October 1, 2021): 106540.
502
          ISSN: 0091-7435, accessed June 2, 2022. https://doi.org/10.1016/j.ypmed.2021.106540. https://www.sciencedirect.
503
          com/science/article/pii/S0091743521001249.
504
     Staib, James, Kierstin Catlett, and Stacey DaCosta Byfield. "Disruptions in cancer screening and diagnoses during
505
          the COVID-19 pandemic in 2020." Publisher: Wolters Kluwer, Journal of Clinical Oncology 39, no. 28 (October
506
          2021): 315–315. ISSN: 0732-183X, accessed June 2, 2022. https://doi.org/10.1200/JCO.2020.39.28 suppl.315.
507
          https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.315.
508
     Suran, Melissa. "Stagnant US Mammography Rates and the Influence of COVID-19." JAMA 327, no. 18 (May 10,
509
          2022): 1742–1744. ISSN: 0098-7484, accessed June 2, 2022. https://doi.org/10.1001/jama.2022.4295. https://doi.org/10.1001/jama.2022.4295.
510
          //doi.org/10.1001/jama.2022.4295.
511
     Velazquez, Ana I., Jessica H. Hayward, Blake Gregory, and Niharika Dixit. "Trends in Breast Cancer Screening
512
          in a Safety-Net Hospital During the COVID-19 Pandemic." JAMA Network Open 4, no. 8 (August 6, 2021):
513
          e2119929. ISSN: 2574-3805, accessed June 2, 2022. https://doi.org/10.1001/jamanetworkopen.2021.19929.
514
          https://doi.org/10.1001/jamanetworkopen.2021.19929.
515
     Williams, Richard. "Using the Margins Command to Estimate and Interpret Adjusted Predictions and Marginal
516
          Effects." The Stata Journal: Promoting communications on statistics and Stata 12, no. 2 (June 2012): 308-331.
517
          ISSN: 1536-867X, 1536-8734, accessed June 2, 2022. https://doi.org/10.1177/1536867X1201200209. http:
518
          //journals.sagepub.com/doi/10.1177/1536867X1201200209.
519
```

20 Supplemental Files

Supplemental Figure 1: Sample Selection Flow Chart




523 Supplemental Figure 2: Mammograms




Supplemental Figure 1 shows the year-by-year proportion of adults reporting having never received a mammogram, having received a mammogram in the past year, having received a mammogram 12 years ago, and having received a mammogram 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

530 Supplemental Figure 3: Pap Smears



Supplemental Figure 3 shows the year-by-year proportion of adults reporting having never received a pap smear, having received a pap smear in the past year, having received a pap smear 1-2 years ago, and having received a pap smear 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

Supplemental Figure 4: Colonoscopies or Sigmoidoscopies



Supplemental Figure 3 shows the year-by-year proportion of adults reporting having never received a colonoscopy or sigmoidoscopy, having received a colonoscopy or sigmoidoscopy in the past year, having received a colonoscopy or sigmoidoscopy or sigmoidoscopy or sigmoidoscopy or sigmoidoscopy or sigmoidoscopy 1-2 years ago, and having received a colonoscopy or sigmoidoscopy 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

Table 2. Marginal Effect Estimates for 2020*Late Group (Linear & Multinomial Logistic Regression Models)

		Model			
		Linear	Logistic		
	Never	-0.029*	-0.028***		
	Nevei	(0.013)	(0.000)		
	<1 Year	-0.021	-0.022		
Mammagram	<1 feat	(0.034)	(0.030)		
Mammogram	1-2 Years	0.031*	0.031***		
	1-2 16015	(0.015)	(0.000)		
	3+ Years	0.020	0.020		
	3+ Years	(0.024)	(0.037)		
	Never	-0.011	-0.010		
	110101	(0.012)	(0.038)		
	<1 Year	-0.043	-0.055		
Pap Smear	Treat	(0.031)	(0.069)		
r up Silicui	1-2 Years	0.042*	0.038*		
	1 2 1 6 6 1 5	(0.019)	(0.027)		
	3+ Years	0.012	0.028		
	J. Tears	(0.018)	(0.019)		
		-0.010	-0.016		
	Never				
		(0.020)	(0.019)		
C-1	<1 Year	-0.035*	-0.043***		
Colonoscopy /		(0.016)	(0.001)		
Sigmoidoscopy	1-2 Years	0.030	0.038		
		(0.016)	(0.084)		
	3+ Years	0.015	0.021		
		(0.019)	(0.024)		

Supplemental - Table 2 reports the 2020*Late effect estimates from our primary linear regression model (left column) and the alternative non-linear multinomail logistic regression model (right column).

^{*} p < 0.05, ** p < 0.01 *** p < 0.001.

Table 3. Sensitivity

		M	ammogra	ım	F	Pap Smea	r	Colonosco	Colonoscopy / Sigmoidoscopy			
		2020*Late	se	Pre-Trend Test (p)	2020*Late	se	Pre-Trend Test (p)	2020*Late	se	Pre-Trend Test (p)		
Alt. 1		-0.028	(0.014)	0.290	-0.013	(0.012)	0.000^	-0.002	(0.020)	0.009^		
Alt. 2	Never	-0.028	(0.015)	0.540	-0.013	(0.012)	0.005^	-0.002	(0.027)	0.081		
Alt. 3		0.005	(0.006)	0.581	-0.013	(0.012)	0.108	0.010	(0.011)	0.010^		
Alt. 1		-0.030	(0.032)	0.047	-0.055	(0.031)	0.110	-0.042*	(0.016)	0.356		
Alt. 2	<1 Year	-0.030	(0.028)	0.368	-0.055*	(0.025)	0.612	-0.042*	(0.020)	0.294		
Alt. 3		-0.047***	(0.012)	0.083	-0.055*	(0.025)	0.008^	-0.043***	(0.009)	0.014		
Alt. 1		0.036*	(0.016)	0.854	0.050*	(0.021)	0.157	0.026	(0.016)	0.207		
Alt. 2	1-2 Years	0.036	(0.023)	0.935	0.050*	(0.022)	0.338	0.026	(0.019)	0.331		
Alt. 3		0.031***	(0.009)	0.398	0.050*	(0.022)	0.933	0.035***	(0.009)	0.416		
Alt. 1		0.022	(0.022)	0.366	0.017	(0.017)	0.011^	0.019	(0.020)	0.001^		
Alt. 2	3+ Year	0.022	(0.024)	0.539	0.017	(0.025)	0.275	0.019	(0.023)	0.260		
Alt. 3		0.011	(0.009)	0.618	0.017	(0.025)	0.056	-0.002	(0.009)	0.085		

Supplemental - Table 3 reports the 2020*Late effect estimates for three alternative linear probability regression models. Alt 1 removes the state-level fixed effects. Alt 2 removes the state-level fixed effects and does not cluster robust standard errors at the state-level, opting only to estimate unclustered robust standard errors. Alt 3 removes fixed effects, does not cluster robust standard errors, and does not weight the analyses by BRFSS supplied sampling weights. *p < 0.05, *p < 0.01 *** p < 0.001.

Table 4. Self-reported rates (2010-2018) of most recent cancer screening for early and late survey groups

	Survey Wave Group									
		E	ary	L	ate	Т	р			
Mammogram	Never	0.342	(0.007)	0.355	(0.009)	1.860	0.200			
	<1 Year	0.400	(0.007)	0.379	(0.008)	-3.000	0.100			
	1-2 Years	0.116	(0.001)	0.121	(0.003)	5.000	0.040			
	3+ Years	0.143	(0.004)	0.145	(0.004)	0.500	0.670			
Pap Smear	Never	0.088	(0.003)	0.102	(0.006)	4.670	0.040			
	<1 Year	0.467	(0.008)	0.420	(0.009)	-5.880	0.030			
	1-2 Years	0.172	(0.003)	0.186	(0.009)	4.670	0.040			
	3+ Years	0.274	(0.008)	0.292	(0.008)	2.250	0.150			
Colon/Sigmoidoscopy	Never	0.417	(0.006)	0.417	(0.012)	0.000	1.000			
	<1 Year	0.211	(0.005)	0.195	(0.008)	-3.200	0.090			
	1-2 Years	0.159	(0.004)	0.146	(0.008)	-3.250	0.080			
	3+ Years	0.213	(0.006)	0.242	(0.010)	4.830	0.040			

Supplemental - Table 4 reports the rates for each mutually exclusive cancer screening category (as a proportion) of the total sample of adults surveyed by BRFSS in years 2010, 2012, 2014, 2016, and 2018.

The rates are stratified by adults surveyed early in the survey wave and adults surveyed later in the survey wave. The t-statistic is the result of the two-sample proportion test.

Table 5. Demographic rates (2010-2018) for early and late survey groups

	Survey Wave Group						
Demographic Group	Eá	arly	L	ate	Т	р	
Age 18-24	0.126	(0.002)	0.134	(0.003)	4.000	0.060	
Age 25-29	0.081	(0.002)	0.091	(0.006)	5.000	0.040	
Age 30-34	0.094	(0.002)	0.103	(0.003)	4.500	0.050	
Age 35-39	0.081	(0.001)	0.088	(0.003)	7.000	0.020	
Age 40-44	0.089	(0.001)	0.088	(0.002)	-1.000	0.420	
Age 45-49	0.080	(0.001)	0.077	(0.001)	-3.000	0.100	
Age 50-54	0.097	(0.001)	0.094	(0.002)	-3.000	0.100	
Age 55-59	0.081	(0.001)	0.081	(0.003)	0.000	1.000	
Age 60-64	0.080	(0.001)	0.077	(0.002)	-3.000	0.100	
Age 65-69	0.061	(0.001)	0.059	(0.003)	-2.000	0.180	
Age 70-74	0.048	(0.001)	0.043	(0.004)	-5.000	0.040	
Age 75-79	0.038	(0.001)	0.030	(0.001)	-8.000	0.020	
Age 80-84	0.043	(0.002)	0.034	(0.002)	-4.500	0.050	
non-Hispanic White	0.659	(0.031)	0.581	(0.065)	-2.520	0.130	
non-Hispanic Black	0.114	(0.011)	0.106	(0.019)	-0.730	0.540	
non-Hispanic other race/ethnicity	0.074	(0.010)	0.100	(0.026)	2.600	0.120	
Hispanic	0.136	(0.027)	0.197	(0.055)	2.260	0.150	
No primary education	0.002	(0.001)	0.003	(0.001)	1.000	0.420	
Primary education only	0.041	(0.005)	0.053	(0.011)	2.400	0.140	
Some High School education, no degree	0.092	(0.002)	0.093	(0.004)	0.500	0.670	
High School degree only	0.285	(0.008)	0.270	(0.015)	-1.870	0.200	
Some college education, no bachelor's degree	0.305	(0.005)	0.308	(0.007)	0.600	0.610	
Bachelor's degree or more	0.274	(0.007)	0.273	(0.007)	-0.140	0.900	
Married	0.524	(0.005)	0.515	(0.009)	-1.800	0.210	
Divorced	0.105	(0.002)	0.101	(0.004)	-2.000	0.180	
Widowed	0.066	(0.002)	0.059	(0.004)	-3.500	0.070	
Seperated	0.024	(0.001)	0.024	(0.001)	0.000	1.000	
Never Married	0.237	(0.005)	0.251	(0.010)	2.800	0.110	
Unmarried Partner	0.044	(0.002)	0.050	(0.005)	3.000	0.100	

Supplemental - Table 5 reports the rates each demographic group (used as independent variables in the primary analysis) of the total sample of adults surveyed by BRFSS in years 2010, 2012, 2014, 2016, and 2018. The rates are stratified by adults surveyed early in the survey wave and adults surveyed later in the survey wave. The t-statistic is the result of the two-sample proportion test.

Table 6. Pre-Trend Tests

		Pre-Treatment Coefficient Estimates								
		2010*Late		2012*Late		2014*Late		2016*Late		Joint Test (p)
	Never	-0.007	(0.018)	0.006	(0.016)	-0.013	(0.014)	-0.018	(0.012)	0.307
Mammagram	<1 Year	-0.012	(0.023)	-0.022	(0.024)	0.002	(0.025)	0.021	(0.021)	0.027
Mammogram	1-2 Years	-0.008	(0.021)	0.000	(0.019)	0.001	(0.020)	-0.001	(0.016)	0.965
	3+ Years	0.027	(0.021)	0.016	(0.018)	0.010	(0.013)	-0.003	(0.015)	0.499
	Never	0.017	(0.011)	-0.009	(0.012)	-0.025**	(0.008)	-0.010	(0.010)	0.000^
Dan Cmoar	<1 Year	0.019	(0.022)	0.018	(0.026)	0.045*	(0.021)	-0.006	(0.015)	0.007^
Pap Smear	1-2 Years	-0.012	(0.014)	-0.018	(0.017)	0.001	(0.017)	0.022	(0.014)	0.319
	3+ Years	-0.024	(0.016)	0.009	(0.019)	-0.021	(0.018)	-0.006	(0.017)	0.249
	Never	0.019	(0.017)	0.015	(0.019)	0.019	(0.019)	-0.024	(0.018)	0.257
Colonoscopy/	<1 Year	-0.030	(0.019)	-0.023	(0.013)	-0.037	(0.023)	-0.009	(0.013)	0.445
Sigmoidoscopy	1-2 Years	0.012	(0.020)	-0.021	(0.015)	0.006	(0.015)	-0.009	(0.013)	0.096
	3+ Years	-0.011	(0.010)	0.014	(0.011)	-0.018*	(800.0)	-0.016	(0.009)	0.002^

Supplemental - Table 6 reports the year-by-year coefficients of the event-history analyses (excluding 2020) with year 2018 as the baseline. Significant coefficients indicate differences in screening rate levels between quasi-treatment cohorts. The Joint Test (p) column reports the p-value from the Wald test, testing if each of the reported coefficient jointly equals zero. The Bonferonni correction was used to account for multiple hypotheses. * p < 0.05, ** p < 0.01, *** p < 0.001. Note: $\land p <$ multiple-test corrected significance level for Joint Test.